EU's CHMP reverses opinion on Gilead's inhaled aztreonam
This article was originally published in Scrip
Executive Summary
Gilead Science's nebulised antibiotic formulation, Cayston (aztreonam lysine) received a positive opinion from the EU's CHMP last week, for short-term use in cystic fibrosis patients, after a re-examination.